Molecular Changes May Precede Inflammation in Early Coronary Atherosclerosis

Heparin-induced thrombocytopenia (HIT) is a serious condition that can occur when patients receive heparin, a medication commonly used to prevent blood clots. This condition involves a significant drop in platelet count and paradoxically increases the risk of dangerous blood clots rather than preventing them. HIT typically develops within 5 to 10 days after starting heparin therapy, though it can occur earlier in patients who have been exposed to heparin in the past. The condition affects approximately 1 to 5 percent of patients receiving unfractionated heparin and less frequently those receiving low molecular weight heparin.

Laboratory testing plays a crucial role in diagnosing HIT. The initial evaluation includes a complete blood count to monitor platelet levels, with a diagnosis typically considered when platelet counts fall by 50 percent or more from baseline or drop below a certain threshold. Two main types of laboratory tests are used to confirm HIT: immunologic assays and functional assays. Immunologic tests, such as enzyme-linked immunosorbent assays (ELISA), detect antibodies against the complex formed by heparin and platelet factor 4 (PF4). These tests are highly sensitive but may produce false-positive results. Functional assays, including the serotonin release assay, measure the actual ability of patient antibodies to activate platelets in the presence of heparin and are considered more specific for diagnosing clinically significant HIT.

The timing and interpretation of HIT testing require careful clinical correlation. Healthcare providers typically use a clinical scoring system, such as the 4Ts score, which evaluates thrombocytopenia severity, timing of platelet count decline, presence of thrombosis, and other potential causes of low platelets. Patients with intermediate to high clinical probability scores should undergo laboratory testing. It is important to note that a positive antibody test alone does not confirm HIT, as some patients develop antibodies without clinical consequences. The combination of clinical assessment and appropriate laboratory testing helps distinguish true HIT from other causes of low platelet counts in hospitalized patients.

When HIT is suspected or confirmed, immediate management changes are necessary. All heparin products must be stopped immediately, and alternative anticoagulants that do not cross-react with HIT antibodies should be initiated. Follow-up platelet counts are essential to monitor recovery, which typically occurs within days to weeks after stopping heparin. Patients diagnosed with HIT should avoid all heparin exposure in the future, and this information should be clearly documented in their medical records to prevent recurrence during subsequent medical procedures or hospitalizations.